UK Markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5900+0.0261 (+4.63%)
At close: 03:59PM EST
Full screen
Loading interactive chart…
  • Globe Newswire

    Freeline Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30, 2022. The Company will continue to trade

  • Globe Newswire

    Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

    Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizing development of FLT201 in Gaucher disease and FLT190 in Fabry disease; ceasing investment in further development of FLT180a in hemophilia B Updated data from first cohort of MARVEL-1 trial show FLT190 continues to be well-toler

  • Globe Newswire

    Freeline to Present at the Stifel Healthcare Conference

    LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York. The fireside chat will take place on November 16th at 8:35 am ET. Senior management will also participate in one-on-one investor meetings during the conference. A live webcast of the fireside chat will be available on the Investors section of Freeline’